For decades, researchers have searched for ways to slow the biological processes that contribute to aging.
While healthy habits such as exercise, nutritious diets, and good sleep remain the foundation of healthy aging, scientists are increasingly exploring whether certain medications might also help.
A new study suggests that semaglutide, a drug already famous for treating diabetes and obesity, may influence some of the body’s aging pathways.
The findings come from researchers at the University of California San Diego and several partner institutions. Their study, published in Nature Communications, examined whether semaglutide affects biological aging in people living with HIV.
HIV has been transformed from a life-threatening disease into a manageable chronic condition thanks to modern antiretroviral treatments. Even so, many people with HIV experience health problems commonly associated with older age earlier than expected.
Scientists have linked this pattern to persistent inflammation, immune system activity, and metabolic changes that continue even when the virus is under control.
To investigate whether semaglutide could influence these processes, researchers studied 108 adults with HIV-associated lipohypertrophy. This condition causes abnormal fat accumulation, particularly around the abdomen, and is often linked to metabolic complications.
Participants received either weekly semaglutide injections or placebo injections over a period of 32 weeks. The researchers then measured biological aging using sophisticated epigenetic clocks.
These tools analyze chemical modifications on DNA known as methylation markers. Scientists have found that these markers can provide insights into how quickly a person’s body is aging biologically, regardless of chronological age.
The results showed a consistent pattern. Participants receiving semaglutide generally displayed slower biological aging compared with those receiving placebo treatment. The drug appeared to affect aging markers connected to multiple organs and systems, including the heart, liver, kidneys, brain, blood, and metabolism.
One of the most notable findings was a 9% reduction in the pace of biological aging according to the DunedinPACE measurement. Researchers also observed improvements in another aging marker associated with mortality risk and age-related diseases.
The study adds to growing evidence that GLP-1 receptor agonists may influence health in ways that extend beyond diabetes and weight management. Scientists believe several factors may contribute to the observed effects.
By reducing inflammation, improving metabolic health, and decreasing harmful fat accumulation around organs, semaglutide may reduce biological stress throughout the body.
Researchers also highlighted results from a separate pilot study involving people with HIV and fatty liver disease.
In that investigation, semaglutide improved aging markers in a substantial proportion of participants, reduced liver fat, and was linked to improvements in physical function. Some participants even showed signs of longer telomeres, protective DNA structures often associated with healthier aging.
Despite the excitement surrounding the findings, researchers urge caution. Semaglutide is not an anti-aging drug, and the results do not mean that people taking the medication will live longer or avoid age-related diseases. The study only suggests that some biological markers associated with aging changed in a favorable direction during treatment.
If you care about diabetes, please read studies about 5 vitamins that may prevent complication in diabetes, and how to manage high blood pressure and diabetes with healthy foods.
For more health information, please see recent studies about vitamin D and type2 diabetes, and to people with type 2 diabetes, some fruits are better than others.
Source: University of California San Diego.
